Common Contracts
2 similar Revenue Interest Assignment and Termination Agreement contracts by Agenus Inc
Execution Version REVENUE INTEREST ASSIGNMENT AND TERMINATION AGREEMENT dated as of September 4, 2015 between INGALLS & SNYDER VALUE PARTNERS, L.P. ARTHUR KOENIG AGENUS INC. and ANTIGENICS LLC Page PURCHASE AND SALE OF THE ASSIGNED INTERESTS...Revenue Interest Assignment and Termination Agreement • May 5th, 2020 • New York
This REVENUE INTEREST ASSIGNMENT AND TERMINATION AGREEMENT (this “Agreement”), dated as of September 4, 2015, is among Ingalls & Snyder Value Partners, L.P. (“Ingalls”), Arthur Koenig (“Koenig”, and together with Ingalls, the “Sellers” and each a “Seller”), Agenus Inc., a Delaware corporation (“Agenus”), and Antigenics LLC, a Delaware limited liability company (as the successor in interest to Antigenics Inc., formerly a Massachusetts corporation) (“AgenMA”, and together with Agenus, the “Purchasers” and each a “Purchaser”). Capitalized terms used but not defined in this Agreement are defined in Section 8.
REVENUE INTEREST ASSIGNMENT AND TERMINATION AGREEMENT dated as of September 4, 2015 between INGALLS & SNYDER VALUE PARTNERS, L.P. ARTHUR KOENIG AGENUS INC. and ANTIGENICS LLCRevenue Interest Assignment and Termination Agreement • September 11th, 2015 • Agenus Inc • Biological products, (no disgnostic substances) • New York
This REVENUE INTEREST ASSIGNMENT AND TERMINATION AGREEMENT (this “Agreement”), dated as of September 4, 2015, is among Ingalls & Snyder Value Partners, L.P. (“Ingalls”), Arthur Koenig (“Koenig”, and together with Ingalls, the “Sellers” and each a “Seller”), Agenus Inc., a Delaware corporation (“Agenus”), and Antigenics LLC, a Delaware limited liability company (as the successor in interest to Antigenics Inc., formerly a Massachusetts corporation) (“AgenMA”, and together with Agenus, the “Purchasers” and each a “Purchaser”). Capitalized terms used but not defined in this Agreement are defined in Section 8.
